E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer

Haibo Wang1, Wenjing Yang2, Qiong Qin1, Xiaomei Yang1, Ying Yang3, Hua Liu1, Wenxiu Lu1, Siyu Gu1, Xuedi Cao1, Duiping Feng4, Zhongtao Zhang5* and Junqi He1*

Abstract

Background: Recurrence and chemoresistance constitute the leading cause of death in colorectal cancer (CRC). Thus, it is of great significance to clarify the underlying mechanisms and identify predictors for tailoring adjuvant chemotherapy to improve the outcome of CRC.

Methods: By screening differentially expressed genes (DEGs), constructing random forest classification and ranking the importance of DEGs, we identified membrane associated guanylate kinase, WW and PDZ domain containing 3 (MAGI3) as an important gene in CRC recurrence. Immunohistochemical and western blot assays were employed to further detect MAGI3 expression in CRC tissues and cell lines. Cell counting kit-8, plate colony formation, flow cytometry, sub-cutaneous injection and azoxymethane plus dextran sulfate sodium induced mice CRC assays were employed to explore the effects of MAGI3 on proliferation, growth, cell cycle, apoptosis, xenograft formation and chemotherapy resistance of CRC. The underlying molecular mechanisms were further investigated through gene set enrichment analysis, quantitative real-time PCR, western blot, co-immunoprecipitation, ubiquitination, GST fusion protein pull-down and immunohistochemical staining assays.

Results: Our results showed that dysregulated low level of MAGI3 was correlated with recurrence and poor prognosis of CRC. MAGI3 was identified as a novel substrate-binding subunit of SKP1-Cullin E3 ligase to recognize c-Myc, and process c-Myc ubiquitination and degradation. Expression of MAGI3 in CRC cells inhibited cell growth, promoted apoptosis and chemosensitivity to fluoropyrimidine-based chemotherapy by suppressing activation of c-Myc in vitro and in vivo. In clinic, the stage II/III CRC patients with MAGI3-high had a significantly good recurrence-free survival (~ 80%, 5-year), and were not necessary for further adjuvant chemotherapy. The patients with MAGI3-medium had a robustly good response rate or recurrence-free survival with fluoropyrimidine-based chemotherapy, and were recommended to undergo fluoropyrimidine-based adjuvant chemotherapy.

© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death, with an estimated 1.8 million new cases and 880,000 attributed deaths in 2018 [1]. The prognosis of CRC is related to the stage at diagnosis, with a 5-year survival rate of approximately 90% for stage I, 70% for stage II, 58% for stage III, and less than 15% for stage IV [2]. To improve the long-term survival rate, it is a standard treatment for patients to receive adjuvant chemotherapy, and fluoropyrimidine [5-fluorouracil (5-FU) or capecitabine]-based systemic adjuvant chemotherapy has been widely used to all stage III CRC patients, and stage II patients with high-risk clinicopathologic features [3, 4]. However, a recent meta-analysis of 25 studies with good quality of reporting find the 5-year recurrence-free survival (RFS) for patients with stage II disease are 82.7% without adjuvant chemotherapy and 79.3% with adjuvant chemotherapy; for stage III disease, the percentages are 49.0% and 63.6% [5], which means that only a few percent of patients benefit from adjuvant chemotherapy, exposing majority of patients to unnecessary toxicity [6]. Thereby, a better understanding of the molecular mechanisms of CRC development to identify a powerful predictor of outcome may seem crucial to tailor adjuvant treatment.

The carcinogenesis and development of CRC is a multi-step process involving numerous genomic alterations. Chromosomal instability, microsatellite instability (MSI), and CpG island methylator phenotype defects are mechanisms involved in colorectal epithelial cell transformation, leading to CRC initiation and progression [7, 8]. Some gene mutations including APC, TP53, SMAD4, KRAS, and several altered molecular signaling pathways are also involved in CRC onset, such as DNA mismatch repair, Wnt/β-catenin, TGF-β/Smad, RAS-MAPK, PI3K/AKT, NF-κb and c-Myc signaling [7–11]. The c-Myc gene is one of the most common overexpressed genes in human tumors, and it is required for the maintenance and development of most cancers including CRC [12, 13].

All of the mentioned mutations and alterations during the initiation and progression of CRC could serve as biomarkers for CRC screening and prognostic evaluation. Microsatellite instability-high (MSI-H) in stage III responds better to immune checkpoint inhibitors. For patients in stage II, MSI-H shows a better prognosis but no beneficial effect of chemotherapy has been observed in this subgroup [14, 15]. KRAS mutational testing in metastatic CRC is part of a standard care to select patients to treatment targeting the EGFR as the presence of a KRAS mutation predicts for insensitivity to the anti-EGFR antibodies [16–18], and BRAF mutation also predicts a lack of benefit from anti-EGFR therapy [19]. There is no evidence so far that CRC patients with KRAS or BRAF-mutated tumors are especially likely to benefit from standard chemotherapy agents [20]. Currently pathological staging is the main prognostic classification

**Conclusions:** MAGI3 is a novel E3 ubiquitin ligase by degradation of c-Myc to regulate CRC development and may act as a potential predictor of adjuvant chemotherapy for CRC patients.

**Keywords:** MAGI3, c-Myc, Colorectal cancer, PDZ, Recurrence, Fluoropyrimidine-based systemic chemotherapy
used in clinical practice to stratify patients for adjuvant chemotherapy [21, 22]. However, about 10% ~ 20% of patients with stage II CRC and 30% ~ 40% of those with stage III CRC develop recurrence, so pathological staging prediction is far from accuracy to meet clinical demands. Therefore, it is of great significance to clarify the mechanisms of carcinogenesis and recurrence to offer opportunities to identify a potential predictor to tailor adjuvant chemotherapy.

In this study, we screened differentially expressed genes (DEGs) in CRC databases from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GSE40967) to gain a panoramic view of expression patterns from tumor vs. adjacent noncancerous tissues and recurrence vs. non-recurrence tumors. Membrane associated guanylate kinase, WW and PDZ domain containing 3 (MAGI3) was identified as a novel independent prognostic marker of CRC patients, with dysregulated low level of MAGI3 correlated with recurrence and poor prognosis. We further provided the convincing evidence that MAGI3 is a novel substrate-binding subunit of SKP1-Cullin E3 ligase to recognize c-Myc, and process c-Myc ubiquitination and degradation. Dysregulated low level of MAGI3 in CRC promoted cell growth and reduced chemosensitivity to fluoropyrimidine-based chemotherapy by promoting activation of c-Myc in vitro and in vivo. In clinical studies, among the stage II/III CRC patients who do not receive adjuvant chemotherapy, patients with MAGI3-high had a significantly good RFS (~80% with 5-year RFS), and were not necessary for further adjuvant chemotherapy. Moreover, for the patients receiving adjuvant chemotherapy, those with MAGI3-medium had a significantly good response rate or RFS with fluoropyrimidine-based chemotherapy, and were recommended to undergo fluoropyrimidine-based adjuvant chemotherapy. The patients with MAGI3-low needed comprehensive treatment including targeted therapy or chemotherapy other than fluoropyrimidine. Taken together, these results suggest that MAGI3 is a novel E3 ubiquitin ligase by degradation of c-Myc to regulate CRC development and may act as a potential predictor of adjuvant chemotherapy for CRC patients.

**Methods**

**Data collection and CRC samples**

The genomic data and clinical data of CRC from TCGA (https://www.cbioportal.org/), GSE40967 and GSE72970 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE40967; GSE72970) were retrieved. The RNA sequencing data from TCGA, GSE40967 and GSE72970 included 375, 566 and 124 samples respectively. Human CRC samples, obtained from First Hospital of Shanxi Medical University (Shanxi Medical University, China) during surgical resection (n = 112), were collected from 2011 to 2014. None of these patients received preoperative chemotherapy or radiotherapy. The study of human CRC samples was approved by the Ethics Committee of First Hospital of Shanxi Medical University, and all of patients provided informed consent.

**Ranking of DEGs importance**

Random forest is a popular classification and regression method that has been proven powerful for various prediction problems in biological studies [23–25]. Mean Decrease Accuracy (MDA), which is involved in the random forest algorithm, is used to rank the important indexes of DEGs. The MDA provides ways to quantify which index contributes most to classification accuracy. A higher MDA indicates that the degree of impurity arising from the category could be reduced farthest by one variable, thus it suggests an important associated index. Statistical analysis is performed using random Forest package of R software (http://www.r-project.org). The specific random forest model parameters were as follows: max features: auto, n estimators: 5000, min sample leaf: 1, and number of variables tried at each split: 4.

**Co-immunoprecipitation (CoIP)**

The method used for immunoprecipitation has been described previously [26]. Briefly, cells were harvested and lysed in lysis buffer (10 mM Heps, 50 mM NaCl, 5 mM EDTA, 1 mM benzamidine, 0.5% Triton X-100). After the lysate was solubilized and clarified, it was incubated with 3 μl antibody and 50 μl protein A/G-agarose for 3 h with end-over-end rotation at 4 °C. After washing three times in 1 ml ice-cold PBS buffer, the immunoprecipitated proteins were eluted from the beads with SDS-PAGE sample buffer and visualized by western blot analysis.

**In vivo xenograft formation and azoxymethane (AOM) / dextran sulfate sodium (DSS) colorectal tumor formation assays**

All animal experiments were performed following the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Use and Care Committee of Capital Medical University. RKO cells (5 × 10^6 cells in 0.1 ml PBS) stable transfected with MAGI3 (RKO-MAGI3) or pcDNA3.0 control (RKO-pcDNA3.0) were subcutaneously implanted into the flank in each of BALB/c nude mice (4–5 weeks old, weight 16-18 g, male, and 4 mice per group). The mice were monitored every two days for the growth of tumors, and they were killed after 15 days. The tumor xenografts were dissected and weighed after the sacrifice of the mice. Tumor volumes were estimated according to the equation: volume (mm^3) = (length × width^2)/2.
AOM/DSS colorectal tumor formation was induced in C57BL/6 mice (5–6 weeks old, weight 18–20 g, male, \( n = 4 \)). Mice were injected intraperitoneally with 10 mg/kg AOM (A5486; Sigma-Aldrich, St. Louis, MO). Seven days after AOM injection, these mice were provided with 2.5% DSS (MB5535; Dalian Meilun Biotechnology Co., Ltd, China) in their drinking water for 7 consecutive days, followed by another 14 days of recovery. This round was repeated triple until day 70, when all mice were sacrificed and their whole colons were collected.

**MAGI3** knockout mice (**MAGI3**/−/−) were generated by Shanghai Model Organisms Center, Inc (Shanghai, China). Genotyping of wild-type and knockout mice was performed with the following primers: forward primer 5’-ATCGCT TGC TTT TCT GAG TGTA-3’ and reverse primer 5’-GGC TTT TCT GAG TGTA-3’. The forward primer 5’-GAA CAC TTT CCC ATG GTG CC-3’ and reverse primer 5’-CCA AAC CAG AGG CCA GGA AT-3’ for wild-type mice; forward primer 5’-GAACACTTCCCATGTTGCC-3’ and reverse primer 5’- CCAACACAGGGCCAGGAT-3’ for **MAGI3**/−/− mice. All mice were on the C57BL/6 background and were maintained under specific-pathogen-free conditions. **MAGI3**/−/− mice and matched wild-type mice received modified AOM/DSS protocol (5–6 weeks old, weight 18–20 g, male, \( n = 4 \)). Mice were injected intraperitoneally with 10 mg/kg AOM. Seven days after AOM injection, these mice were provided with 2.5% DSS in their drinking water for 7 consecutive days. All mice were sacrificed and their whole colons were collected at day 66. Disease activity index (DAI) score is the sum of stool consistency change (0, none; 2, loose stool; and 4, diarrhea), bleeding (0, none; 1, trace; 2, mild hemoccult; 3, obvious hemoccult; and 4, gross bleeding) and weight loss (0, none; 1, 0–5%; 2, 5–10%; 3, 10–20%; and 4, >20%) and then divided by three. Mice were scored for the DAI at the same time of each day, and DAI score was recorded every three days.

**Glutathione S-transferase (GST) fusion protein pull-down assay**

GST pull-down assay was described previously [27]. In brief, GST-c-Myc-wt, GST-c-Myc-∆ct and GST-SKP1 fusion proteins were induced and purified from bacteria (BL21) according to the manufacturer’s protocol, and then re-suspended in PBS containing 0.5% Nonidet P-40 and protease inhibitors. Equal amounts of GST fusion proteins (conjugated on beads) were incubated with 1 ml cell lysates with end-over-end rotation at 4°C for 4 h. The beads were washed 4 times with washing buffer I (10 mM HEPES, 50 mM NaCl, 5 mM EDTA, 1 mM benzamidine, 0.1% Tween 20, and 3% bovine serum albumin), then washed 1 time with washing buffer II (buffer I without 3% bovine serum albumin). The proteins were eluted from the beads with 2 × SDS-PAGE sample buffer, resolved via SDS-PAGE, and detected by western blotting.

**Statistics analysis**

All experiments were repeated at least 3 times. Data were statistical analyzed by SPSS 16.0 (IBM, Armonk, NY, USA) and GraphPad Prism software (GraphPad, CA, USA). Continuous variables were analyzed by analysis of variance or t-test, and nonparametric test was used if the data did not assume Gaussian distribution. A chi-square test or fisher exact test was used to compare the distribution differences between the two groups. Pearson correlation was employed to assess the correlation of variables, and spearman correlation was used if the data did not assume Gaussian distribution. The Kaplan–Meier (KM) survival curves and log-rank test were used to determine the differences in survival rates between two groups. Cox proportional hazards model was employed to perform univariate and multivariate analysis. Data were presented as mean±SEM. \( P < 0.05 \) was considered statistically significant, and one or two-tailed \( P \)-value was used in analyses.

**Additional methods**

More details regarding the methods can be found in supplementary materials (Supplementary materials and methods).

**Results**

**Low level of MAGI3 is correlated with recurrence in CRC**

To identify genes associated with CRC recurrence, a total of 17 DEGs were identified from two independent
Fig. 1 (See legend on previous page.)
that overexpression of MAGI3 significantly inhibited CRC cell proliferation (Fig. 2a) and colony formation (Fig. 2b). We further observed that knockdown of MAGI3 expression in HT29 or SW480 CRC cells with relatively high levels of MAGI3 (Additional file 4: Fig. S2A, C) significantly enhanced cell proliferation (Fig. 2c) and clonogenicity (Fig. 2d). Meanwhile, overexpression of MAGI3 significantly promoted CRC cell cycle arrest (Fig. 2e) with the changed expression of proliferation and cell cycle related proteins, such as PCNA, p21, cyclinD1, and CDK4 (Additional file 4: Fig. S2D). Conversely, knockdown of MAGI3 in HT29 or SW480 cells markedly decreased CRC cell cycle arrest (Fig. 2f). Furthermore, overexpression of MAGI3 increased CRC cell apoptosis (Fig. 2g) with activation of caspases and PARP (Additional file 4: Fig. S2E), and knockdown of MAGI3 reduced cell apoptosis in CRC cells (Fig. 2h). Taken together, our results suggest that MAGI3 acts as a tumor suppressor by regulating proliferation and apoptosis in CRC cells.

MAGI3 modulates c-Myc degradation through the ubiquitin proteasome pathway and regulates c-Myc transcriptional target genes expression

To gain insight into the molecular mechanism of MAGI3 expression control cell functions, Gene Set Enrichment Analysis (GSEA) was performed. The results showed that the gene signatures of c-Myc targets were enriched in patients with MAGI3 lower levels in TCGA CRC and GSE40967 datasets (Fig. 3a). The results were further verified in our cell studies that overexpression of MAGI3 in RKO cell downregulated the expression of a panel of genes classically promoted by c-Myc, such as CDK4, CDC25A, CCNA2, CCND2, PCNA and ELF4E, and upregulated the expression of a panel of genes classically inhibited by c-Myc, as CDKN1A, CASP3 and GADD45A. Furthermore, the converse results were observed when MAGI3 was knocked down in HT29 cell (Fig. 3b). Taken together, these results indicate that MAGI3 inhibited c-Myc activation.

Our further experiments showed that MAGI3 could regulate c-Myc expression. Overexpression of MAGI3 in CRC cells markedly decreased c-Myc protein levels, whereas knockdown of MAGI3 in CRC cells significantly

MAGI3 regulates proliferation and apoptosis of CRC cells

Tumor cell proliferation is a major representative indicator of malignant phenotype, so the effects of MAGI3 expression on CRC cell proliferation was investigated. First, HT115 and RKO CRC cell lines with low levels of MAGI3 (Additional file 4: Fig. S2A) were stably transfected with MAGI3 (Additional file 4: Fig. S2B), and the data showed
Fig. 2 (See legend on previous page.)
increased c-Myc protein levels (Fig. 3c). To explore the underlying mechanism, we first tested MAGI3 on c-Myc expression at transcriptional level. As the results shown, neither overexpression nor knockdown of MAGI3 had detectable effect on c-Myc mRNA levels (Fig. 3d), and there were no correlations between MAGI3 and c-Myc mRNA in clinical specimens (Fig. 3e). We then examined the expression of MAGI3 on c-Myc protein stability, and found that the half-life of c-Myc protein was markedly decreased with MAGI3 overexpression (Fig. 3f and Additional file 4: Fig. S3A) and significantly increased by knockdown of MAGI3 in CRC cells (Fig. 3g and Additional file 4: Fig. S3B). c-Myc protein is reported to be mainly regulated by the ubiquitin proteasome pathway [30], so we investigated whether MAGI3 modulated c-Myc stability through proteasome pathway. We found that c-Myc protein levels were robustly increased in CRC cells overexpressed MAGI3 after treated with MG132, a proteasome inhibitor (Fig. 3h; lane 3, 4). Meanwhile, blocked proteasome activation with MG132, c-Myc protein levels were less affected by MAGI3 overexpression (Fig. 3h; lane 2, 4). These results indicate that MAGI3 regulates c-Myc expression through proteasome pathway. To confirm the results, the ubiquitination of c-Myc was detected in the presence or absence MAGI3. The enhanced c-Myc ubiquitination and reduced c-Myc protein level were observed in RKO cell overexpressed MAGI3 (Fig. 3i; lane 2, 4). Conversely, knockdown of MAGI3 reduced c-Myc ubiquitination and increased c-Myc protein level in HT29 cell (Fig. 3j; lane 2, 4). As expected, when cells were treated with MG132, a distinct c-Myc ubiquitination could be detected coordinately with MAGI3 manipulated, but no significant c-Myc protein levels were changed (Fig. 3i and j; lane 3, 5). Furthermore, we found that MAGI3 modulated c-Myc ubiquitin in Lys48-linked polyubiquitylation (Fig. 3k). Taken together, these data demonstrate that MAGI3 modulates c-Myc protein stability by promoting c-Myc ubiquitin–proteasome degradation, thereby regulates c-Myc signaling.

MAGI3 is identified as a novel substrate-binding subunit of SKP1-Cullin E3 ligase to recognize c-Myc protein

MAGI3 is a scaffold protein containing PDZ domain, and c-Myc constitutes a potential PDZ domain binding motif (PBM) at its C-terminus (N-S-C-A), so there is possible an interaction between MAGI3 and c-Myc. Our CoIP results confirmed the association between endogenous MAGI3 and c-Myc in CRC cells (Fig. 4a), and the association was further validated by reciprocal CoIP of the exogenous tagged protein in HEK293 cells (Fig. 4b). The GST-pulldown assays further clarified the structural determinants of the MAGI3/c-Myc interaction that the fifth PDZ domain of MAGI3 directly bound with the c-Myc (Fig. 4c), with the PBM of c-Myc is required for the interaction (Fig. 4d). Abolished this interaction, c-Myc ubiquitination was no more upregulated by MAGI3 (Fig. 4e). All together, these results indicate that the MAGI3/c-Myc interaction is essential for MAGI3 upregulation of c-Myc ubiquitination and degradation.

The SKP1-Cullin-F-box protein (SCF) ubiquitin-protein ligases are the most abundant E3 ubiquitin ligases contribute to c-Myc degradation. F-box proteins, such as FBXW7, SKP2 and STUB1, are well established substrate-recognition components of SCF E3 ligase to specifically target c-Myc [31–33]. However, knockdown of FBXW7, SKP2 or STUB1 had little effect on c-Myc ubiquitination caused by MAGI3, whereas knockdown of SKP1, an adaptor in SCF complex, dramatically eliminated c-Myc ubiquitination and degradation caused by MAGI3 overexpression (Fig. 4f), indicating that MAGI3 is a novel substrate-binding subunit assembling c-Myc with SKP1 to form an E3 ligase. It was further verified by robust signals of c-Myc, SKP1 and CUL1 detected in the MAGI3 CoIP complex (Fig. 4g), and MAGI3 directly interacted by the ubiquitin pathway. a, Enrichment plots of GSEA showed that the gene signatures of c-Myc targets were significantly enriched in low MAGI3 expression CRC specimens. b, MAGI3 inhibited c-Myc transcriptional target genes expression. Heatmap of c-Myc target genes expression modulated by MAGI3 in RKO or HT29 cells (three independent experiments). c, Overexpression of MAGI3 decreased, whereas knockdown of MAGI3 increased the protein levels of c-Myc. c-Myc protein levels were detected by western blot in HT115 or RKO cells over-expressed MAGI3 (left), and in HT29 or SW480 cells silenced MAGI3 (right). d, MAGI3 had no detectable effect on the c-Myc expression at mRNA level. qPCR analysis of the c-Myc mRNA expression in RKO or HT29 cells with the indicated MAGI3 modulation, three independent experiments, data were presented as the mean ±SEM, a 2-tailed, unpaired t test was used to determine statistical significance. ***P<0.001, NS, no significance. e, MAGI3 and c-Myc had no correlation (by Pearson’s) at transcriptional level in CRC specimens from TCGA (left, n=375) and GSE40967 (right, n=566). f and g, Overexpression of MAGI3 decreased, whereas knockdown of MAGI3 prolonged the half-life of c-Myc. The effect of MAGI3 on the half-life of c-Myc were detected by western blot in CRC cells treated with CHX. The protein half-life curves were obtained by quantifying three independent experiments (right). h, MAGI3 regulated c-Myc turn over through proteasome pathway. The levels of c-Myc protein were detected by western blot in CRC cells transfected with MAGI3 and treated with MG132 (10 μM) for 6 h before harvesting. i and j, Overexpression of MAGI3 promoted, whereas knockdown of MAGI3 inhibited c-Myc ubiquitin. Ubiquitination assays of c-Myc in lysates from RKO or HT29 cells with the indicated MAGI3 manipulation. k, MAGI3 regulated c-Myc ubiquitin in Lys48-linked poly-ubiquitination. Ubiquitination assays of c-Myc in RKO cells transfected with HA-Ub or HA-Ub/K48R.
Fig. 3 (See legend on previous page.)
with SKP1 via its second PDZ domain (Fig. 4h). Thereby, as the schematic diagram shown (Fig. 4i), these results demonstrate the existence of a macromolecular complex c-Myc-MAGI3-SKP1-CUL1, and PDZ domain of MAGI3 alternates with F-box domain, mediates the SKP1-Cullin E3 ligase targeting c-Myc, and processes c-Myc proteasome degradation.

**MAGI3 inhibits CRC development through downregulation of c-Myc protein**

To delineate whether MAGI3 suppresses CRC cell proliferation by targeting c-Myc, cell proliferation was detected in CRC-MAGI3 cells in presence or absence of c-Myc overexpression. Data showed that overexpression of c-Myc significantly promoted proliferation of HT115 or RKO cells. Overexpression of MAGI3 inhibited proliferation of HT115 or RKO cells, and downregulated c-Myc protein levels, which were consistent with our previous results. However, when c-Myc levels were overexpressed by transfection of c-Myc plasmid (Fig. 5a), the inhibition abilities of MAGI3 to CRC cells proliferation or colony formation were greatly reduced (Fig. 5b and c). Additionally, MAGI3 levels were not affected following overexpression of c-Myc in CRC cells (Additional file 4: Fig. S4A). In vivo animal experiment, MAGI3 overexpression inhibited the growth of CRC xenografts in nude mice within 15 days (Fig. 5d), and MAGI3 overexpression correlated with the reduced c-Myc expression (Fig. 5e). In AOM/DSS induced CRC of C57BL/6 mice, the expression of MAGI3 was robustly reduced coordinate with c-Myc increase compared with matched surrounding tissues (Fig. 5f). Furthermore, in our modified model of AOM/DSS induced CRC, MAGI3−/− mice showed higher disease activity index and a significant higher tumor number and load compared to their wild-type controls (Additional file 4: Fig. S4B-E). In clinical CRC specimens, levels of MAGI3 protein were negatively correlated with expression levels of c-Myc (r = -0.45, Fig. 6a and b). Consistently, mRNA level of MAGI3 was negatively correlated with the first principal component of c-Myc signaling activation (Fig. 6c). Taken together, these data indicate that MAGI3 inhibits CRC cells proliferation and CRC development through suppression of c-Myc expression and activity. Moreover, besides CRC, loss of MAGI3 expression correlated with activation of c-Myc downstream effectors in multiple carcinomas (Fig. 6d and Additional file 4: Fig. S5).

**MAGI3 regulates sensitivity of chemotherapy by inhibition of c-Myc signaling and acts as a predictor for chemotherapy response in CRC**

It is well known that a high level of c-Myc is closely correlated with chemotherapy resistance in many cancers, including CRC cell [34–36], reminding that dysregulated low level of MAGI3 in CRC may reduce chemosensitivity through accumulation of c-Myc. In this study, we found that overexpression of MAGI3 significantly enhanced sensitivity of RKO cell to 5-FU or oxaliplatin (OXA) (Fig. 7a). Conversely, knockdown of MAGI3 robustly decreased sensitivity of HT29 cells to 5-FU or OXA (Fig. 7b). In clinical, a significant high ratio of response (complete response or partial response) to fluoropyrimidine-based chemotherapy was observed in the CRC patients with MAGI3-high than those of MAGI3-low at mRNA level (86.7% vs. 54.8%, Fig. 7c), indicating MAGI3 correlated with chemotherapy response both in vitro and in vivo. Additionally, the patients with response to chemotherapy had significantly high level of MAGI3 than that of patients with non-response (NR, stable disease and progressive disease) (Fig. 7d), and the gene signature of cell proliferation and c-Myc activation were enriched in the non-response group (Fig. 7e and f) although mRNA level of c-Myc had no statistical difference between two groups (Fig. 7g). These results were further validated with an independent cohort (Additional file 4: Fig. S6). Thus, these findings provide first lines of evidences that loss of MAGI3 expression in CRC patients activates c-Myc.
signaling, and contributes to chemotherapy resistance in CRC.

MAGI3 as a predictive biomarker for adjuvant chemotherapy in CRC patients was further explored in this study. Clinical specimens of CRC patients in stage II/III without adjuvant chemotherapy from the TCGA were stratified into two groups by MAGI3 mRNA level with MAGI3-high (95%CI, 602 ~ 693) and MAGI3-medium/
low (95% CI, 355~394). KM survival analysis revealed that the patients of MAGI3-high had a significantly better RFS than the patients of MAGI3-medium/low (75% vs. 46% with 10-year RFS, Fig. 7h), suggesting that patients of MAGI3-high were not necessary for further adjuvant chemotherapy to avoid overtreatment. Subsequently, the patients of non-high MAGI3 (mRNA level ≤ 602), who underwent adjuvant chemotherapy, were explored their chemosensitivity to fluoropyrimidine-based systemic chemotherapy. These patients were stratified into three groups by MAGI3 mRNA level (602~486, 475~404, and 388~196), and response rates to fluoropyrimidine-based chemotherapy were 100%, 80% and 60%, respectively (Fig. 7i). These results were further validated in an independent Chinese cohort with information of RFS and MAGI3 protein level. Consistently, among the patients in stage II/III without adjuvant chemotherapy, those of MAGI3-high (MAGI3 protein level H-score ≥ 8) had a significantly better RFS than those of MAGI3-non-high (H-score < 8) (80% vs. 47% with 5-year RFS, Fig. 7j). Furthermore, among the patients receiving fluoropyrimidine-based systemic adjuvant chemotherapy, those of MAGI3-medium (H-score 4~8) had a significantly better RFS than those of MAGI3-low (H-score 1~3) (75% vs. 39% with 5-year RFS, Fig. 7k). Therefore, the patients with high MAGI3 are not necessary for further adjuvant chemotherapy to avoid overtreatment. The patients with MAGI3 in medium level are subsequently recommended to undergo fluoropyrimidine-based systemic adjuvant chemotherapy. Whereas, the patients with MAGI3 in low level may need comprehensive treatment including radiation therapy or targeted therapy. Taken together, these data indicate that MAGI3 is a potential independent predictive biomarker for chemotherapy in CRC patients.

**Discussion**

Pathological staging is the major prognostic classification currently used in clinical practice to tailor patients for adjuvant chemotherapy [37, 38], but its prediction is far from accuracy to meet clinical demands. Here, we showed that low level of MAGI3 correlated with recurrence and poor prognosis of CRC by screening and validating from multi-central cohorts over a thousand cases. Low MAGI3 was identified as a risk factor of poor survival, and a predictor of CRC recurrence independent on pathological features, as well as MSI-H, KRAS and BRAF mutations. Understanding of the mechanisms by which CRC downregulates MAGI3 expression may provide new therapeutic targets for treatment of this disease. Norén et al. reported that in inflammatory bowel disease, which can further develop into CRC, inflammation was associated with decreased levels of MAGI3 [39]. In addition, based on the analysis of TCGA database, we found that methylation of MAGI3 promoter and miRNA regulation may also be the cause of down-regulate MAGI3 expression in CRC. However, the underlying molecular mechanism need to further explored.

MAGI3 have been reported binding with PTEN and β-catenin to regulate PI3K/AKT and Wnt signaling respectively, to inhibit tumor formation and progression [40, 41]. However, no study was reported the significance of these interactions in CRC cells. Analysis of TCGA database with GSEA found that gene signatures of PI3K/AKT and Wnt signaling activation were not enriched with MAGI3 level (data not shown), reminding that MAGI3 was not involved in PI3K/AKT or Wnt signaling activation in CRC cells. Recently, Yun and his colleagues reported that MAGI3 by interaction with LPA2 and phospholipase C-β3, could decrease the tumorigenic capacity via inhibition of LPA-induced activation of NF-kB and JNK in colon cancer cells [42]. However, this conclusion was also not supported by the data from TCGA (data not shown). Given that CRC is a heterogeneous disease with genetic profiles and clinical outcomes associate with the anatomic location of the primary tumor, these results could not exclude the possibility of MAGI3/LPA2 interaction in some distinct types of CRC. Nevertheless, it is unlikely the major function of MAGI3 in CRC cells.
In this study, MAGI3 is found to promote c-Myc protein ubiquitin–proteasome degradation, subsequently attenuates c-Myc activation in a broad range of cancers besides CRC. Studies in CRC cells reveal that MAGI3 expression inhibits cell proliferation and increase cell apoptosis by downregulation of c-Myc.
Fig. 6  MAGI3 is negatively associated with c-Myc in CRC specimens and multiple carcinomas. **a**, The negative correlation of MAGI3 and c-Myc protein levels in clinical CRC specimens. Representative IHC staining of MAGI3 and c-Myc in 108 cases of CRC samples. Scale bars: 50 μm. Right panels are × 2 magnification of the dashed areas on the left. **b**, Pearson correlation analysis between MAGI3 and c-Myc in 108 cases of CRC samples. **c**, MAGI3 level negatively correlated with c-Myc activation in CRC patients. MAGI3 expression level was measured by RNA-Seq in 375 CRC samples from TCGA. Gene signature of c-Myc activation was defined as gene sets, DANG REGULATED BY MYC UP (the gene signature of c-Myc positive activation) and DANG REGULATED BY MYC DN (the gene signature of c-Myc negative activation) from the Molecular Signatures Database. The First Principal Component (PC1) of the c-Myc positive signature was negatively correlated with MAGI3 expression (left); while the PC1 of c-Myc negative signature was positively correlated with MAGI3 expression (right) (Pearson correlation). **d**, Enrichment plots of GSEA showed that the gene signatures of c-Myc positive activation were significantly enriched in low MAGI3 expression groups in esophageal squamous cell carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and thyroid carcinoma (THCA).
Fig. 7 Loss of MAGI3 reduces sensitivity of chemotherapy by upregulation of c-Myc activation in CRC patients. a and b, Overexpression of MAGI3 increased, whereas knockdown of MAGI3 reduced CRC cells chemosensitivity to 5-FU or OXA. CRC cells with MAGI3 overexpressed (a) or knocked down (b) were treated with 5-FU or OXA in different concentrations for 48 h, and the cells viability were measured by CCK-8 assays (three independent experiments). c, The result of chi-square test showed that the patients with high MAGI3 mRNA level had high response ratio to chemotherapy. d, Scatter plots of MAGI3 mRNA expression in patients with NR and R. e and f, Enrichment plots of GSEA showed that the gene signatures of cell proliferation (e), c-Myc positive activation (f, left) were enriched in NR group and c-Myc negative regulated pathway (f, right) was enriched in R group. g, Scatter plots of c-Myc mRNA expression in patients with NR and R. h, KM survival curve indicated that among the patients from TCGA without adjuvant chemotherapy, those with high MAGI3 mRNA level had a better RFS than those with medium/low MAGI3 (log-rank test). i, The fisher exact test showed that among the patients receiving adjuvant chemotherapy, those with relatively medium MAGI3 mRNA level (602 ~ 486) had significantly high response rate to fluoropyrimidine-based chemotherapy than those with relatively low MAGI3 (388 ~ 196). j, KM survival curve showed that among the patients from Shanxi Medical University without adjuvant chemotherapy, those with high MAGI3 protein level (H-score ≥ 8) had a better RFS than those with medium/low MAGI3 (H-score < 8). k, KM survival curve showed that among the patients receiving adjuvant chemotherapy, those with medium MAGI3 protein (H-score 4 ~ 8) had a better RFS than the patients with low MAGI3 (H-score 1 ~ 3). Data were presented as the mean ± SEM, 2-way repeated-measures ANOVA with Bonferroni post-test (a and b), the chi-square test (c), nonparametric Mann–Whitney test (d and g), fisher exact test with 1-sided (i) were used to determine statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001 and NS, no significance.
oncogenic activities. These results are further confirmed by our in vivo studies of subcutaneous xenograft tumor, AOM/DSS induced CRC model and clinical specimens. Thereby, these findings demonstrate that MAGI3 plays an important role in CRC progression.

c-Myc is an unstable protein with a half-life of less than 30 min in non-transformed cells due to rapid turnover through the ubiquitin–proteasome system, and the SCF are the most abundant E3 ligases contribute to c-Myc degradation. Typically, F-box proteins such as FBXW7, SKP2 and STUB1, are the substrate-recognition components of SCF E3 ligase to target c-Myc [31–33]. Interestingly, our studies show that none of these F-box proteins is indispensable in regulation of c-Myc ubiquitination and degradation under the MAGI3 overexpressed condition. However, this did not suggest that MAGI3 have stronger effect than F-box proteins on the ubiquitination and degradation of c-Myc, as MAGI3 is also not indispensable in regulation of c-Myc ubiquitination and degradation when FBXW7 is overexpressed (data not shown). Knockdown either of MAGI3 or FBXW7 does not significantly alter the ubiquitination and degradation of c-Myc when the other one overexpressed. It is likely that MAGI3 and F-box proteins have function in partial redundancy in c-Myc degradation. In this study, MAGI3 is identified as a substrate-binding subunit assembled with SKP1 via a novel interface between SKP1 and the second PDZ domain of MAGI3 to form a macromolecular complex of E3 ligases MAGI3-SKP1-CUL1. MAGI3 subsequently binds c-Myc through PBM of c-Myc at its carboxyl terminal and the fifth PDZ domain of MAGI3 to associate c-Myc with the SKP1-Cullin3 E3 ligase, and modulates c-Myc poly-ubiquitination and degradation. To the best of our knowledge, this is the first report that MAGI3 acts as a substrate-specific binding protein of E3 to recognize c-Myc, and PDZ domain of MAGI3 is a novel domain to adapt the SKP1-Cullin3 E3 to recognize c-Myc.

Another interesting point find from this study is that MAGI3 plays an essential role in CRC chemosensitivity and acts as a potential predictor of adjuvant chemotherapy response in CRC patients. Overexpression of MAGI3 significantly enhances chemosensitivity, whereas knockdown of MAGI3 decreases the chemosensitivity to 5-FU or OXA. Analysis of chemosensitivity of CRC patients in three independent cohorts over 213 cases reveals that high MAGI3 levels are associated with good response to fluoropyrimidine-based chemotherapy. Loss of MAGI3 expression in CRC patients activate c-Myc signaling, contribute to chemotherapy resistance in CRC. Lines of evidences report that c-Myc overexpression increase chemoresistance attributing to a highly efficient DNA double stranded breaks repair system offsetting the genomic instability induced by chemotherapy, or suppression of pro-apoptotic machinery. In this study, we find that MAGI3 overexpression promotes cell apoptosis, whereas knockdown of MAGI3 suppresses cell apoptosis. Also, our GSEA results show that the gene signatures of DNA double stranded breaks repair are enriched in CRC patients with low MAGI3 (data not shown). These results again indicate that MAGI3 regulates chemosensitivity of CRC cells via c-Myc.

In this study, we also investigate MAGI3 as a predictor for fluoropyrimidine-based adjuvant chemotherapy. The data reveal that among the stage II/III CRC patients from two independent cohorts (TCGA and a Chinese cohort) without adjuvant chemotherapy, the patients with high MAGI3 levels have significantly good RFS (~80% with 5-year RFS) at both mRNA and protein levels. The patients with MAGI3-medium levels (mRNA level 486~602, or protein level H-score 4~8) have significantly good response rate (100%) or RFS (80% with 5-year RFS) with fluoropyrimidine-based chemotherapy. Thereby, the patients with high MAGI3 (mRNA level >602, protein level H-score >8) are not necessary for further adjuvant chemotherapy; the patients with medium MAGI3 (mRNA level 486~602, protein level H-score 4~8) are subsequently recommended to undergo fluoropyrimidine-based adjuvant chemotherapy; the patients with low MAGI3 (mRNA level <486, protein level H-score <4) need comprehensive treatment including radiotherapy or targeted therapy. Taken together, all these results suggest that MAGI3 is a novel predictor marker to tailor adjuvant chemotherapy to improve outcome of CRC patients.

A limitation of this study is inadequately sized cohorts of CRC patients to study MAGI3 as a potential predictor for response to fluoropyrimidine-based chemotherapy, and especially in the absence of a prospectively assessed cohort. Thus, these conclusions need to be further confirmed in multiple studies with larger-scale validation across different populations.

In summary, the present study has identified MAGI3 as a novel tumor suppressor in CRC and demonstrated its inhibition on proliferation by targeting c-Myc. We provide the convincing evidence for the first time that MAGI3 is a novel E3 ubiquitin ligase by degradation of c-Myc to regulate CRC development. The loss of MAGI3 correlates with an unfavorable prognosis, and it is a potential predictive biomarker for fluoropyrimidine-based chemotherapy in CRC patients.

Abbreviations
AOM: Azoxymethane; AUC: Area under curve; CCK-8: Cell counting kit-8; CEA: Carcinoembryonic antigen; CHX: Cyclohexamide; CI: Confidence interval; CoIP: Co-immunoprecipitation; CRC: Colorectal cancer; DAI: Disease activity index;
DEGs: Differentially expressed genes; DSS: Dextran sulfate sodium; GSEA: Gene set enrichment analysis; GST: Glutathione S-transferase; H-score: Histochemical score; IHC: Immunohistochemical; KM: Kaplan–Meier; MAGI3: Membrane associated guanylate kinase; WW and PDZ domain containing 3; MDA: Mean density area; MSI: Microsatellite instability; MSI-H: Microsatellite instability-high; OS: Overall survival; OXA: Oxaliplatin; PC1: First principal component; qPCR: Quantitative real-time-PCR; RFS: Recurrence-free survival; ROC: Receiver operating characteristic; RT-PCR: Reverse transcription PCR; SCF: SKP1-Cullin-F-box protein; siRNA: Small interfering RNA; TCGA: The cancer genome atlas; 5-FU: 5-Fluorouracil.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12943-022-01622-9.

**Additional file 1:** Table S1. The sequences of siRNA. Table S2. The gene sets of GSEA. Table S3. The sequence of primers. Table S4. The primary antibodies for western blot, CoIP and IHC. (doc: 92KB)

**Additional file 2:** Supplementary materials and methods. (doc: 63KB)

**Additional file 3:** Table S1. Ranking the importance of 17 differentially expressed genes. Table S2. Univariate and multivariate Cox regression analyses of potential poor prognostic factors in colorectal cancer. Table S3. Univariate and multivariate Cox regression analyses of potential poor prognostic factors in colorectal cancer from TCGA. Table S4. GSEA for low MAGI3 colorectal cancer patients from TCGA and GSE40967. (doc: 135KB)

**Additional file 4:** Figure S1. Low MAGI3 expression is correlated with the poor prognosis of CRC patients. (A and B) Scatter plot of MAGI3 mRNA in adjacent noncancerous tissues and tumor tissues (A), non-recurrence tumors and recurrence tissues (B) from databases of TCGA and GSE40967. Data were shown as mean ± SEM, and statistical significance was calculated by 2-tailed, unpaired t test. *P<0.05, **P<0.01, ***P<0.001. (C and D) KM survival curve showing comparison of the OS and RFS between MAGI3-low and -high expression groups of CRC patients from TCGA (C) and GSE40967 (D) databases. *P<0.05, calculated by log-rank test. (E) Scatter plots of MAGI3 mRNA expression in MSI-H and MSS patients from TCGA. (F) Scatter plots of MAGI3 mRNA expression in KRAS mutation and KRAS mutation-free patients from TCGA. (G) Scatter plots of MAGI3 mRNA expression in BRAF normal and BRAF normal patients from TCGA. Data were presented as the mean ± SEM, 2-tailed, unpaired t test (E and F), nonparametric Mann-Whitney test (G) were used to determine statistical significance. NS, no significance. **Figure S2:** MAGI3 induces cell cycle arrest and apoptosis in CRC cells. (A) Protein levels of MAGI3 in indicated CRC cell lines were analyzed by western blot. (B) Establishment and identification of CRC cell lines with stable expression of exogenous MAGI3. Overexpression of MAGI3 in HT115 and RKO cells were confirmed by RT-PCR and western blot analysis. (C) Knockdown of MAGI3 by small interference RNA transfection in HT29 and SW480 cells were confirmed by RT-PCR and western blot analysis. (D) MAGI3 overexpression altered cell cycle-related protein expression. (E) MAGI3 overexpression upregulated apoptosis-related proteins expression in CRC cells. Figure S3. MAGI3 modulates c-Myc protein stability. (A) The half-life of c-Myc protein was markedly decreased with MAGI3 overexpression in HT115 cells. (B) The half-life of c-Myc protein was robustly increased by knockdown of MAGI3 in SW480 cells. The half-life curves of c-Myc protein were obtained by quantifying three independent experiments with western blot (right). Data were presented as the mean ± SEM, a 2-tailed, unpaired t test used to determine statistical significance. *P<0.05, **P<0.01, ***P<0.001. Figure S4. Knockout of MAGI3 in mice promotes the development of inflammatory CRC. (A) Overexpression of c-Myc had no detectable impacts on MAGI3 expression in HT29 and SW480 cells by western blot analysis. (B) Representative images of whole colons of WT, MAGI3-/- mice at the end of the modified AOM/DSS protocol. The right image is ×2 magnification of the dashed areas on the left, in which the blue area is the mucosal surface flipped after the colon is cut off. (C) The DAI scores of MAGI3-/- mice increased dramatically compared with WT mice during modified AOM/DSS protocol treatment. (D and E) The tumor numbers and tumor load were analyzed in WT and MAGI3-/- mice at the end of modified AOM/DSS protocol. Data were presented as the mean ± SEM. Statistical significance was determined by 2-way ANOVA with Bonferroni post-tests (C), Mann-Whitney test (D) and fisher exact test (E). *P<0.05, **P<0.01, ***P<0.001. **Figure S5:** MAGI3 expression is downregulated in multiple tumor tissues. Scatter plot of MAGI3 mRNA in adjacent noncancerous tissues and tumor tissues of BLCA, ESCA, HNSC, KIRC, KIRP, LUAD, LUSC, THCA and UCEC from databases of TCGA. Data were shown as mean ± SEM, and statistical significance was calculated by 2-tailed, unpaired t test. *P<0.05, **P<0.01, ***P<0.001. BLCA, bladder cancer; ESCA, esophageal squamous cell carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.

**Figure S6.** Loss of MAGI3 expression in CRC patients reduces sensitivity of chemotherapy by upregulation of c-Myc protein level and activation. (A) The chi-square test showed that the CRC patients from dataset GSE72970 with high MAGI3 mRNA level had high response ratio to chemotherapy. (B) Scatter plots of MAGI3 mRNA expression in patients with non-response (NR) or response (R). (C and D) Enrichment plots of GSEA showed that the gene signatures of cell proliferation (C), c-Myc positive activation (D, left) were enriched in NR group and c-Myc negative regulated pathway (D, right) was enriched in R group. (E) Scatter plots of c-Myc mRNA expression in patients with non-response (NR) or response (R). Data were presented as the mean ± SEM, the chi-square test (A), 2-tailed, unpaired t test (B and E) were used to determine statistical significance. *P<0.05 and NS, no significance. (PDF 1.86MB)

**Acknowledgements**

We would like to thank TCGA CRC database, GSE40967 and GSE72970 database. We also thank for the convenient online analysis tool provided by Omicshare.

**Authors’ contributions**

HW and JH designed the research and prepared the manuscript as senior authors. HW performed most of the experiments. WY and WL performed iHC experiments. HW, WY, WL, SG and XC contributed to the computational analysis and the statistical analysis. ZZ, QQ, XY, YY and HL shared research materials. DF provided human samples. JH, ZZ and XY managed and supervised the research. All authors reviewed the results and approved the final version of the manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of the People’s Republic of China (No. 81572333, 81772707, 81972732); Beijing Municipal Natural Science Foundation (No. 7192020, 7182016).

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study of human CRC samples was approved by the Ethics Committee of First Hospital of Shanxi Medical University (2020-K065), and all of patients provided informed consent. All animal procedures were under the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the study was approved by the Capital Medical University Animal Care and Use Committee.

**Consent for publication**

All subjects have written informed consent.

**Competing interests**

The authors have declared that no competing interest exists.

**Author details**

1Beijing Key Laboratory for Tumor Invasion and Metastasis, Department of Biochemistry and Molecular Biology, Capital Medical University, No.10
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Johnston PG. Stage II. Colorectal cancer: to treat or not to treat. Oncol. 2005;10:332–4.
3. Al BBI, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzywoska MK, Maroun J, McAllister P, Cutsem EV, et al. American society of clinical oncology recommendtions on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.
4. Messersmith WA. Systemic management of colorectal cancer. J Natl Compr Canc Net. 2017;15:699–702.
5. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009;4:343–64.
6. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367–86.
7. Starr TK, AIIawt R, Silverstein KAT, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O’Sullivan MG, Matsie I, Dupuy AJ, et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science. 2009;323:1747–50.
8. Parsons DW, Wang TL, Samuels Y, Gallois C, Laurent-Puig P, Bonetti F, Taiel B. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol. 2017;28:958–68.
9. Siroky DS. Navigating random forests and related advances in algorithmic modeling. Statistics Surveys. 2009;3:147–63.
10. Song S, Hong JC, McDonnell SE, Koong AC, Minsky BD, Chang DT, Liauw SL. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012;19:2471–6.
11. Tangantino A, Warschow PK, Schmed M, Glieder T, Eberhard C, Buecher MW, Ullrich A. Predictive value of CEA for survival in stage I rectal cancer: a population-based propensity score-matched analysis. J Gastrointest Surg. 2016;20:1213–22.
12. Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, Hazama S, Takayama Y, Nakayama K, Iizuka H, et al. The F-box protein Skp2 participates in c-Myc prososomal degradation and acts as a cofactor for c-myc-regulated transcription. Mol Cell. 2003;11:189–200.
13. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004;101:9085–90.
14. Paul I, Ahmed SF, Bhovimik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32:1284–95.
15. Elbdawy M, Usui T, Yamawaki H, Sasaki K. Development of an experimental model for analyzing drug resistance in colorectal cancer. Cancers. 2018;10:164.
16. Elbdawy M, Usui T, Yamawaki H, Sasaki K. Emerging roles of C-Myc in cancer stem cell-related signaling and resistance to cancer chemotherapy: a potential therapeutic target against colorectal cancer. Int J Mol Sci. 2019;20:2340.
17. Usui T, Sakurai M, Umata K, Elbdawy M, Ohama T, Yamawaki H, Hazama S, Takayama Y, Nakayama K, Iizuka H, et al. The F-box protein Skp2 participates in c-Myc prososomal degradation and acts as a cofactor for c-myc-regulated transcription. Mol Cell. 2003;11:189–200.
18. Hari DM, Leung AM, Lee J, Sim M, Qiu A, Chou CG, Kelch AK. A/CCR cancer staging manual 7th edition criteria for colon cancer: do the complex survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26:131–21.
19. Lieve R, Bachet J-B, Boige V, Cayer A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:74–9.
20. Waring P, Tiej, Maru D, Karapetis CS. RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer. Clin Colorectal Canc. 2016;15:95–103.
21. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxalplatin or irinotecan: results from the MRC Focus Trial. J Clin Oncol. 2009;27:5931–7.
22. Schmolli HJ, Van Cutsem E, Stein A, Valentinii V, Gilmelis B, Haustermann K, Northinger B, van de Velde CJ, Balmana J, Regula J, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.
23. Benson III Al B, Venook AP, Al-Hawary MM, Cederquist L, Chen YI, Ciombor KK, Cohen S, Cooper H, Deming D, Engstrom P, et al. NCCN guidelines insights colon cancer, version 2.2018-updated features to the NCCN guidelines. J Natl Compr Canc Net. 2018;16:359–69.
24. Jostiffleimer A, Uhn K, A novel variation selection approach using random forests. Comput Stat Data An. 2013;60:50–69.
25. Stephan J, Stegle O, Beyer A. A random forest approach to capture genetic effects in the presence of population structure. Nat Commun. 2015;6:7432.
modifications improve prognostic assessment? J Am Coll Surgeons. 2013;217:181–90.

38. Benson AB III, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Erzinger PC, Ficarra A, et al. Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:370–98.

39. Norén E, Almer S, Söderman J. Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease. BMC Gastroenterol. 2017;17:68.

40. Ma Q, Yang Y, Feng D, Zheng S, Meng R, Fa P, Zhao C, Liu H, Song R, Tao T, et al. MAGI3 negatively regulates Wnt/β-catenin signaling and suppresses malignant phenotypes of glioma cells. Oncotarget. 2015;6:35851–65.

41. Qian Ma, Yan Z, Ran M, Kunming X, Ying X, Song L, Zonglin He, Tao T, Ying Y, Jizong Z, et al. MAGI3 suppresses glioma cell proliferation via upregulation of PTEN expression. Biomed Environ Sci. 2015;28:502–9.

42. Lee SJ, Ritter SL, Zhang H, Shim H, Hall RA, Yun CC. MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology. 2011;140:924–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.